FDA Shopping For 3D Tissue Bioprinter, Cosmetic Contamination Testing Services
This article was originally published in The Rose Sheet
Executive Summary
Recent procurement activities show an agency increasingly focused on cosmetics’ safety vis-a-vis microbial threats and, in the case of talc-containing products, asbestos. Meanwhile, FDA seeks a 3D bioprinter to use in organ toxicity studies as an alternative to traditional animal models.